Tempus AI, Inc. (TEM)
| Market Cap | 13.53B |
| Revenue (ttm) | 1.11B |
| Net Income (ttm) | -203.88M |
| Shares Out | 177.91M |
| EPS (ttm) | -1.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,145,237 |
| Open | 70.70 |
| Previous Close | 70.29 |
| Day's Range | 70.70 - 76.41 |
| 52-Week Range | 31.36 - 104.32 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 78.83 (+3.64%) |
| Earnings Date | Nov 4, 2025 |
About TEM
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharma... [Read more]
Financial Performance
In 2024, Tempus AI's revenue was $693.40 million, an increase of 30.38% compared to the previous year's $531.82 million. Losses were -$746.33 million, 180.6% more than in 2023.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for TEM stock is "Strong Buy." The 12-month stock price target is $78.83, which is an increase of 3.64% from the latest price.
News
Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Piper Sandler 37th Annual Healthcar...
Tempus AI: Opportunity To Build Position
Tempus AI has pulled back with the broader AI sector, presenting a renewed buying opportunity after strong Q3 results. TEM's Q3 sales surged 85% to $334 million, largely driven by the Ambry acquisitio...
Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and bei...
Tempus AI, Inc. (TEM) Presents at Stifel 2025 Healthcare Conference Transcript
Tempus AI, Inc. ( TEM) Stifel 2025 Healthcare Conference November 13, 2025 10:00 AM EST Company Participants James Rogers - Chief Financial Officer Conference Call Participants Daniel Arias - Stifel,...
Tempus AI: Great Buying Opportunity On Recent Weakness
Tempus AI stands out as a leader in healthcare AI, showing strong execution and robust Q3 results despite recent stock volatility. TEM reported 85% revenue growth, expanding gross margins, and solid p...
Tempus AI: A Good Bet For The Future Of Health Care
Tempus AI remains a buy as its data set, testing volumes, and financial results continue to show robust growth. TEM's Genomics segment drives strong revenue growth, with oncology and hereditary testin...
Tempus AI: First Positive EBITDA, Huge TAM - Yet The Stock Isn't A Buy
Tempus AI is building a strong moat in healthcare AI with vast clinical/genomic datasets and robust infrastructure, driving high-growth potential. TEM achieved its first positive adjusted EBITDA in Q3...
Tempus AI Growth Outlook Boosted By Higher ASPs, Pharma Contracts, Analyst Says
BTIG analyst Mark Massaro reiterated a Buy rating for Tempus AI, Inc. (NASDAQ:TEM) with a price target of $96 following the third-quarter FY25 earnings beat.
Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presen...
Tempus AI, Inc. (TEM) Q3 2025 Earnings Call Transcript
Tempus AI, Inc. ( TEM) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Elizabeth Krutoholow - Vice President of Investor Relations & Competitive Intelligence Eric Lefkofsky - ...
Tempus Reports Third Quarter 2025 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...
Tempus to Participate in the Stifel 2025 Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Stifel 2025 Healthcare Conference o...
Tempus to Report Third Quarter 2025 Financial Results on November 4
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on...
Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in genetic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a peer-reviewed study in...
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therap...
Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presen...
Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Pr...
Tempus AI's $100 Breakout — Billionaire Cliff Asness Reaps 60% Windfall
Tempus AI Inc (NASDAQ:TEM) has become one of 2025's most dramatic comeback stories. The stock soared past $100 this week, marking a new 52-week high and sending the market buzzing about the AI-powered...
Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution.
Overlooked Stock: TEM Taps All-Time High on FDA Clearance
Tempus AI's (TEM) RNA-based vitro diagnostic device got clearance from the FDA for use. The company reached record highs on Monday's session but pulled back by the closing bell.
Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearanc...
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes NEW YORK , Sept. 15, ...
Tempus AI stock is cheap as Murrey Math Lines points to more gains
Tempus AI stock price surged to a record high on Wednesday after the healthcare-focused artificial intelligence company announced a major breakthrough from the Food and Drug Administration (FDA). It j...
Tempus AI: Is TEM Stock A 10x Growth Story?
Great news for Tempus AI stock! The company has just received FDA approval for an upgraded version of its Tempus Pixel platform — a cardiac imaging system that uses advanced AI to deliver highly accur...
Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging
On Thursday, Tempus AI, Inc. TEM received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform.